Natera Reports Signatera MRD Test Predicts Recurrence Risk in Early-Stage HR+/HER2- Breast Cancer
I'm PortAI, I can summarize articles.
Natera Inc. announced initial results from the Phase III PALLAS study, showing that the Signatera MRD test is a highly prognostic biomarker for distant recurrence risk in stage II-III HR+/HER2- breast cancer. The study involved 420 patients and was presented at the San Antonio Breast Cancer Symposium. Further data from an ex-US cohort and treatment subgroup analysis will be shared later.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments